Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
12:20pm, Friday, 31'st Jan 2025
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Friday, 31'st Jan 2025
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stre
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
05:07am, Friday, 31'st Jan 2025
Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch. Fourth-quarter net sales rose
Novartis CEO says U.S. exit from global health programmes to affect millions
05:00am, Friday, 31'st Jan 2025
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide.
Novartis beats consensus on Q4 earnings
01:14am, Friday, 31'st Jan 2025
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues.
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
01:00am, Friday, 31'st Jan 2025
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc 1 , +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
02:39pm, Thursday, 30'th Jan 2025
As AbbVie Inc. ABBV and Novartis AG NVS prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.
10 Undervalued Dividend Growth Stocks: January 2025
09:00am, Wednesday, 29'th Jan 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an
Novartis to Report Q4 Earnings: What's in the Offing?
02:40pm, Tuesday, 28'th Jan 2025
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
US appeals court lifts pause on generic version of Novartis' Entresto
04:08pm, Thursday, 16'th Jan 2025
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
12:09pm, Thursday, 16'th Jan 2025
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet
Novartis loses emergency bid to block Entresto generic in US
07:01pm, Wednesday, 15'th Jan 2025
A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug En
Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
02:57pm, Tuesday, 14'th Jan 2025
Novartis AG (NYSE:NVS ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vo
Novartis CEO: We need to get Europe to pay its fair share
01:00pm, Tuesday, 14'th Jan 2025
Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
10:19am, Tuesday, 14'th Jan 2025
CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
